ARWR vs RNA

Arrowhead Pharmaceuticals maintains strong 10x growth potential within 3-5 years, leveraging its advanced TRiM RNAi platform and a robust pipeline targeting high-value indications. The positive Phase 3 data for ARO-AAT (fazirsiran) in Alpha-1 Antitrypsin Deficiency, recently announced (Q4 2025/early Q1 2026), remains a pivotal catalyst, positioning the company for imminent regulatory submission an...

Avidity Biosciences (RNA) continues to demonstrate strong 10x growth potential, sustained by its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. The lead asset, AOC 1001 for Myotonic Dystrophy Type 1 (DM1), remains critically important, with the path to potential regulatory filing in late 2026/early 2027 still intact. This timeline, coupled with ongoing clinical progress for AOC 102...